Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway

PLoS ONE

Volumn 2, Issue 12, 2007, Pages

  Vitale, Ilio ^a,b,c   Galluzzi, Lorenzo ^a,b,c   Vivet, Sonia ^a,b,c   Nanty, Lisa ^a,b   Dessen, Philippe ^b,c,d   Senovilla, Laura ^a,b,c   Olaussen, Ken A ^a,b,c   Lazar, Vladimir ^b,c,d   Prudhomme, Michelle ^e   Golsteyn, Roy M ^f   Castedo, Maria ^a,b,c   Kroemer, Guido ^a  

^a Institut Gustave Roussy   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d CNRS   (France)

^e UNIVERSITÉ CLERMONT AUVERGNE   (France)

^f INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUB1 RELATED PROTEIN; CHECKPOINT KINASE 1; CISPLATIN; MUTANT PROTEIN; PROTEIN MAD2; PROTEIN P53; PUMA PROTEIN; SMALL INTERFERING RNA; PROTEIN KINASE;

ADAPTATION; ANEUPLOIDY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL DEATH; COLON CANCER; CONTROLLED STUDY; DIPLOIDY; ENZYME INHIBITION; FEMALE; GENETIC TRANSFECTION; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; MITOSIS; MOUSE; NONHUMAN; STRESS; TETRAPLOIDY; TUMOR CELL; TUMOR XENOGRAFT; DRUG EFFECT; MITOSIS SPINDLE; PHYSIOLOGY; POLYPLOIDY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; HUMANS; MITOTIC SPINDLE APPARATUS; POLYPLOIDY; PROTEIN KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 42749091176     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001337     Document Type: Article

References (60)

1. Shi Q, King RW (2005) Chromosome nondisjunction yields tetraploid rather than aneuploid cells in human cell lines. Nature 437: 1038-1042.
2. Duelli D, Lazebnik Y (2003) Cell fusion: a hidden enemy? Cancer Cell 3: 445-448.
3. Ogle BM, Cascalho M, Platt JL (2005) Biological implications of cell fusion. Nat Rev Mol Cell Biol 6: 567-575.
4. Storchova Z, Pellman D (2004) From polyploidy to aneuploidy, genome instability and cancer. Nat Rev Mol Cell Biol 5: 45-54.
5. Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, et al. (2005) Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 437: 1043-1047.
6. Margolis RL (2005) Tetraploidy and tumor development. Cancer Cell 8: 353-354.
7. Castedo M, Roumier T, Blanco J, Ferri KF, Barretina J, et al. (2002) Sequential involvement of Cdkl, mTOR and p53 in apoptosis induced by the HIV-1 envelope. Embo J 21: 4070-4080.
8. Castedo M, Coquelle A, Vivet S, Vitale I, Kauffmann A, et al. (2006) Apoptosis regulation in tetraploid cancer cells. Embo J 25; 2584-2395.
9. Andreassen PR, Lohez OD, Lacroix FB, Margolis RL (2001) Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. Mol Biol Cell 12: 1315-1328.
10. Tsuchihara K, Lapin V, Bakal C, Okada H, Brown L, et al. (2005) Ckap2 regulates aneuploidy, cell cycling, and cell death in a p53-dependent manner. Cancer Res 65: 6685-6691.
11. Sugimoto M, Gromley A, Sherr CJ (2006) Hzf, a p53-responsive gene, regulates maintenance of the G2 phase checkpoint induced by DNA damage. Mol Cell Biol 26: 502-512.
12. Aylon Y, Michael D, Shmueli A, Yabota N, Nojima H, et al. (2006) A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev 20: 2687-2700.
13. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, et al. (2004) Cell death by mitotic catastrophe: a molecular definition. Oncogene 23: 2825-2837.
14. Waldman T, Lengauer C, Kinzler KW, Vogelstein B (1996) Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381: 713-716.
15. Tighe A, Johnson VL, Taylor SS (2004) Truncating APC mutations have dominant effects on proliferation, spindle checkpoint control, survival and chromosome stability. J Cell Sci 117: 6339-6353.
16. Wang X, Zhou YX, Qjao W, Tominaga Y, Ouchi M, et al. (2006) Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation, Oncogene 25: 7148-7158.
17. Incassati A, Patel D, McCance DJ (2006) Induction of tetraploidy through loss of p53 and upregulation of Plk1 by human papillomavirus type-16 E6. Oncogene 25: 2444-2451.
18. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, et al. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864-870.
19. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, et al. (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434: 907-913.
20. Nevanlinna H, Bartek J (2006) The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 25; 5912-5919.
21. Zhou BB, Sausville EA (2003) Drug discovery targeting Chk1 and Chk2 kinases. Prog Cell Cycle Res 5: 413-421.
22. Syljuasen RG, Sorensen CS, Nylandsted J, Lukas C, Lukas J, et al. (2004) Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation. Cancer Res 64: 9035-9040.
23. Furuta T, Hayward RL, Meng LH, Takemura H, Aune GJ, et al. (2006) p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine. Oncogene 25: 2839-2849.
24. Tao ZF, Lin NH (2006) Chk1 inhibitors for novel cancer treatment. Anticancer Agents Med Chem 6: 377-388.
25. Pawelek JM (2005) Tumour-cell fusion as a source of myeloid traits in cancer. Lancet Oncol 6: 988-993.
26. Duelli DM, Hearn S, Myers MP, Lazebnik Y (2005) A primate virus generates transformed human cells by Fusion. J Cell Biol 171: 493-503.
27. Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, et al. (2004) The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res 64: 7629-7633.
28. Heselmeyer K, Schrock E, du Manoir S, Blegen H, Shah K, et al. (1996) Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci U S A 93: 479-484.
29. Bjelkenkrantz K, Lundgren J, Olofsson J (1983) Single-cell DNA measurement in hyperplastic, dysplastic and carcinomatous laryngeal epithelia, with special reference to the occurrence of hypertetraploid cell nuclei. Anal Quant Cytol 5: 184-188.
30. Cuvelier CA, Morson BC, Roels HJ (1987) The DNA content in cancer and dysplasia in chronic ulcerative colitis. Histopathology 11: 927-939.
31. Barres DR, Duhr MA, Boivin YA (1985) Discrimination between precancerous and cancerous lesions of the uterine cervix by DNA measurements on tissue sections. Anal Quant Cytol Histol 7: 320-326.
32. Van Dyke DL, Worsham MJ, Benninger MS, Krause CJ, Baker SR, et al. (1994) Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region. Genes Chromosomes Cancer 9: 192-206.
33. Buhmeida A, Backman H, Collan Y (2002) DNA cytometry in diagnostic cytology of the prostate gland. Anticancer Res 22: 2397-2402.
34. Nelson DA, Tan TT, Rabson AB, Anderson D, Degenhardt K, et al. (2004) Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev 18: 2095-2107.
35. Castedo M, Coquelle A, Vitale I, Vivet S, Mouhamad S, et al. (2006) Selective resistance of tetraploid cancer cells against DNA damage-induced apoptosis. Ann N Y Acad Sci 1090: 35-49.
36. Guerra S, Lopez-Fernandez LA, Garcia MA, Zaballos A, Esteban M (2006) Human gene profiling in response to the active protein kinase, interferon-induced serine/threonine protein kinase (PKR), in infected cells. Involvement of the transcription factor ATF-3 IN PKR-incluced apoptosis. J Biol Chem 281: 18734-18745.
37. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C (2000) The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 14: 289-300.
38. Tse AN, Schwartz GK (2004) Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Cancer Res 64: 6635-6644.
39. Levesque AA, Kohn EA, Bresnick E, Eastman A (2005) Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints. Oncogene 24: 3786-3796.
40. Chen Z, Xiao Z, Gu WZ, Xue J, Bui MH, et al. (2006) Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int J Cancer 119: 2784-2794.
41. Petermann E, Maya-Mendoza A, Zachos G, Gillespie DA, Jackson DA, et al. (2006) Chk1 requirement for high global rates or replication fork progression during normal vertebrate S phase. Mot Cell Biol 26: 3319-3326.
42. Durkin SG, Arlt MF, Howlett NG, Glover TW (2006) Depletion of CHK1, but not CHK2, induces chromosomal instability and breaks at common fragile sites. Oncogene 25: 4381-4388.
43. Niida H, Tsuge S, Katsuno Y, Konishi A, Takeda N, et al. (2005) Depletion of Chk1 leads to premature activation of Cdc2-cyclin B and mitotic catastrophe. J Biol Chem 280: 39246-39252.
44. Tang J, Erikson RL, Liu X (2006) Checkpoint kinase 1 (Chk1) is required for mitotic progression through negative regulation of polo-like kinase 1 (Plk1). Proc Natl Acad Sci U S A 103: 11964-11969.
45. Zachos G, Black EJ, Walker M, Scott MT, Vagnarelli P, et al. (2007) Chk1 is required for spindle checkpoint function. Dev Cell 12: 247-260.
46. Sampath D, Cortes J, Estrov Z, Do M, Shi Z, et al. (2006) Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 107: 2517-2524.
47. Lara PN Jr, Mack PC, Synold T, Frankel P, Longmate J, et al. (2005) The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res 11: 4444-4450.
48. Zhao H, Piwnica-Worms H (2001) ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 21: 4129-4139.
49. Damia G, Filiberti L, Vikhanskaya F, Carrassa L, Taya Y, et al. (2001) Cisplatinum and taxol induce different patterns of p53 phosphorylation. Neoplasia 3: 10-16.
50. Zermati Y, Mouhamad S, Stergiou L, Besse B, Galluzzi L, et al. (2007) Non-apoptotic role for Apaf-1 in the DNA damage response. Mol Cell in press.
51. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB (2007) p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/ MK2 pathway for survival after DNA darnage. Cancer Cell 11: 175-189.
52. Asher G, Lotem J, Tsvetkov P, Reiss V, Sachs L, et al. (2003) P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1. Proc Natl Acad Sci U S A 100: 15065-15070.
53. Gatei M, Sloper K, Sorensen C, Syljuasen R, Falck J, et al. (2003) Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem 278: 14806-14811.
54. Stevens C, Smith L, La Thangue NB (2003) Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol 5: 401-409.
55. Boya P, Andreau K, Poncet D, Zamzami N, Perfettini JL, et al. (2003) Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J Exp Med 197: 1323-1334.
56. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interrerence in cultured mammalian cells. Nature 411: 494-498.
57. Criollo A, Galluzzi L, Chiara Maiuri M, Tasdemir E, Lavandero S, et al. (2007) Mitochondrial control of cell death induced by hyperosmotic stress. Apoptosis 12: 3-18.
58. Galluzzi L, Zamzami N, de La Motte Rouge T, Lemaire C, Brenner C, et al. (2007) Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis.
59. Perfettini JL, Castedo M, Roumier T, Andreau K, Nardacci R, et al. (2005) Mechanisms of apoptosis induction by the HIV-1 envelope. Cell Death Differ 12 Suppl 1: 916-923.
60. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61.